Overview
- Four senators—Jeanne Shaheen, Susan Collins, Raphael Warnock and John Kennedy—announced a bipartisan framework to reintroduce the INSULIN Act, setting a $35 monthly limit for many privately insured patients starting in 2027.
- The plan requires health plans to waive deductibles for selected insulin products and, in 2028, charge the lesser of $35 or 25% of the plan’s negotiated price.
- Uninsured patients would gain access to $35 insulin through a five-year pilot in 10 states chosen by HHS, backed by a $100 million fiscal 2027 authorization, a grant program, and a national resource center and hotline.
- The bill targets middlemen known as pharmacy benefit managers by passing all insulin rebates to health plans so savings reach patients, and it promotes more competition from lower-cost biosimilar and generic insulin.
- The Endocrine Society endorsed the measure, while sponsors work to attach it to must-pass legislation and seek support from Senate Majority Leader John Thune and President Trump, with some coverage tying the effort to Trump’s drug-price agenda.